The long-term objectives of this research proposal are to acquire a thorough understanding of the mechanisms of action and of resistance to Taxol, an antitumor agent that is known to be efficacious in the treatment of human cancer. Knowledge gained from the studies described in this proposal will improve our ability to design Taxol analogs with a better therapeutic index, to develop strategies to reverse or overcome drug resistance and to understand the synergy between Taxol and discodermolide that we have reported in tissue culture cells. Our understanding of Taxol will be applied to other natural products such as the epothilones and discodermolide whose mechanisms of action and resistance have major similarities, but are not identical, to those of Taxol. The specific objectives of the research proposal are to: 1. Define the binding site(s) for epothilone B and discodermolide in the microtubule and determine the relationship between these binding sites and that of Taxol. Drug analogs with radiolabeled photoreactive substituents at defined positions in the molecules will be used to determine the sites of interaction between the drug and its target, the microtubule. 2. Investigate the basis of resistance to Taxol, epothilone and discodermolide in drug resistant cell lines that do not express P-glycoprotein. Tubulin harboring mutations will be analyzed for functional alterations. We will also determine if Taxol, epothilone and discodermolide bind preferentially to a single beta-tubulin isotype. These experiments will take advantage of a new mass spectrometry-based method that has been developed in our laboratory for the analysis of the C-terminal diversity of a- and beta-tubulin isotypes. 3. Determine if the synergism between Taxol and discodermolide that has been demonstrated in four cancer cell lines in our laboratory can be attributed to specific structural/functional characteristics of discodermolide. The study will take advantage of unique discodermolide analogs in a series of in vitroand mouse experiments.
| Yang, Chia-Ping Huang; Wang, Changwei; Ojima, Iwao et al. (2018) Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of ?-Tubulin and the Multidrug Resistance Associated P-Glycoprotein. J Nat Prod 81:600-606 |
| Mathew, Deepti; Wang, Yanhua; Van Arsdale, Anne et al. (2018) Expression of ?V-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia. Int J Gynecol Cancer 28:363-370 |
| Nadaradjane, Celine; Yang, Chia-Ping Huang; Rodriguez-Gabin, Alicia et al. (2018) Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners. J Nat Prod 81:607-615 |
| Samaraweera, Leleesha; Adomako, Alfred; Rodriguez-Gabin, Alicia et al. (2017) A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC. Sci Rep 7:1900 |
| Prota, Andrea E; Bargsten, Katja; Redondo-Horcajo, Mariano et al. (2017) Structural Basis of Microtubule Stabilization by Discodermolide. Chembiochem 18:905-909 |
| Yang, Chia-Ping Huang; Horwitz, Susan Band (2017) Taxol®: The First Microtubule Stabilizing Agent. Int J Mol Sci 18: |
| Yang, Chia-Ping Huang; Yap, Eng-Hui; Xiao, Hui et al. (2016) 2-(m-Azidobenzoyl)taxol binds differentially to distinct ?-tubulin isotypes. Proc Natl Acad Sci U S A 113:11294-11299 |
| Frimer, Marina; Levano, Kelly S; Rodriguez-Gabin, Alicia et al. (2016) Germline mutations of the DNA repair pathways in uterine serous carcinoma. Gynecol Oncol 141:101-7 |
| Andreopoulou, Eleni; Schweber, Sarah J; Sparano, Joseph A et al. (2015) Therapies for triple negative breast cancer. Expert Opin Pharmacother 16:983-98 |
| Hou, June Y; McAndrew, Thomas C; Goldberg, Gary L et al. (2014) A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference? Reprod Sci 21:532-7 |
Showing the most recent 10 out of 55 publications
